• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase.

作者信息

Ueno T, Kobayashi N, Maekawa T

出版信息

Thromb Haemost. 1979 Oct 31;42(3):885-94.

PMID:505403
Abstract

Pharmacokinetics of intravenously injected 125I-labeled urokinase (125I-UK) of a molecular weight of 33,000 daltons in normal rabbits and patients with various diseases were investigated. The plasma clearance of 125I-UK in rabbits was described by a biexponential curve within six hours with a half-life of 8 minutes, 2.3 hours, respectively. The radioactivity in the liver and kidneys 15 minutes after iv injection with 125I-UK was 9.6% and 14.0% of the radioactivity injected, respectively. Approximately 80% of the total radioactive material injected was excreted in the urine in 18 hours. No increase in activator activity in the urine was observed after a large amount of UK injection. Activity uptake of 125I-UK by experimentally induced arterial thrombus was little. Lysis of the stasis thrombus was produced by injecting 7.5 x 10(-4) IU of UK in only one out of 8 rabbits. In vitro contact experiment revealed that transfer of 125I-UK to plasma clot is slow (24 hours for 10% of 125I-UK by plasma clot). In 4 patients plasma clearance of 125I-UK was essentially similar to that in rabbits. From the results obtained optimal dosage regimen of UK administration for complete thrombolysis in vivo was discussed.

摘要

相似文献

1
Studies on metabolism of urokinase and mechanism of thrombolysis by urokinase.
Thromb Haemost. 1979 Oct 31;42(3):885-94.
2
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.人尿激酶原酶及其活性形式的生物学和溶栓特性——III. 天然和重组尿激酶在实验性颈静脉血栓形成兔中的溶栓特性
Thromb Haemost. 1984 Aug 31;52(1):27-30.
3
Comparative study of the activity of high and low molecular weight urokinase in the presence of fibrin.纤维蛋白存在下高分子量和低分子量尿激酶活性的比较研究
Thromb Haemost. 1982 Feb 26;47(1):36-40.
4
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
5
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.人尿激酶原酶及活性形式的生物学和溶栓特性——IV. 几种哺乳动物血浆纤溶反应的变异性
Thromb Haemost. 1984 Aug 31;52(1):31-3.
6
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys.人尿激酶原酶及活性形式的生物学和溶栓特性——II. 兔和松鼠猴体内天然及重组尿激酶的代谢
Thromb Haemost. 1984 Aug 31;52(1):24-6.
7
Pharmacokinetics of single chain forms of urokinase-type plasminogen activator.单链尿激酶型纤溶酶原激活剂的药代动力学
J Pharmacol Exp Ther. 1987 Jul;242(1):245-50.
8
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.
9
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.人尿激酶原酶及其活性形式的生物学和溶栓特性——I. 从人尿中获得或通过重组DNA技术制备的尿激酶在人血浆中的体外纤溶和纤维蛋白原溶解特性
Thromb Haemost. 1984 Aug 31;52(1):19-23.
10
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase.血浆中组织型纤溶酶原激活物的快速作用抑制剂也是尿激酶的主要血浆抑制剂。
Thromb Haemost. 1986 Feb 28;55(1):65-9.

引用本文的文献

1
Beyond nimodipine: advanced neuroprotection strategies for aneurysmal subarachnoid hemorrhage vasospasm and delayed cerebral ischemia.超越尼莫地平:用于治疗动脉瘤性蛛网膜下腔出血血管痉挛和迟发性脑缺血的高级神经保护策略。
Neurosurg Rev. 2024 Jul 5;47(1):305. doi: 10.1007/s10143-024-02543-5.
2
Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.不同的受体介导组织型纤溶酶原激活剂和尿激酶的肝脏分解代谢。
Biochem J. 1990 May 1;267(3):647-52. doi: 10.1042/bj2670647.